Oncodia AB has moved to new premises
April 1, 2020
Following the eventful nine months spent at the premises of BASE10, on 1st of April, 2020 Oncodia’s team moved to a new location. The office
Menu
Cancer diagnostics.
Easy, accurate, now!
Our vision is a world where every cancer patient receives the right therapy.
Our mission is to help the advancement of cancer precision medicine.
Product portfolio
We empower healthcare providers with CE/IVD-certified solutions from the tissue handling to the data analysis step of the diagnostic process.
CE-IVD software for analyses of sequencing data from tumors to guide the use of targeted cancer therapies and immuno-checkpoint inhibitors
Fully automated CE-IVD extraction solutions for DNA and RNA without manual reagent handling
Helping our customers to set their workflows for sample isolation and data analysis
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. We are committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Our focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Oncodia has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 876876
Eureka
Eit Health
Eurostars
Uppsala Innovation Centre
News
Oncodia expands offering to include DNA and RNA extraction for molecular pathology
October 29, 2019
Oncodia has acquired the assets of ExScale Biospecimen Solutions AB, including the rights to reagent kits and software CE marked for IVD for automated extraction
Oncodia wins EuroStars grant
October 1, 2019
A multidisciplinary project for personalized ovarian cancer therapy selection, termed 3D-SELECT, was granted EUR €3.47 million, of which total subsidy ~ €1.82 million, on June
Get in touch
About
Improving the use of advanced cancer drugs by providing healthcare systems with solutions for highly accurate mutation detection.